1258 related articles for article (PubMed ID: 27815602)
1. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
[TBL] [Abstract][Full Text] [Related]
2. Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate.
Potkin SG; Loze JY; Forray C; Baker RA; Sapin C; Peters-Strickland T; Beillat M; Nylander AG; Hertel P; Nitschky Schmidt S; Eramo A; Hansen K; Naber D
Int J Neuropsychopharmacol; 2017 Jan; 20(1):40-49. PubMed ID: 27927736
[TBL] [Abstract][Full Text] [Related]
3. Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
Kim E; Correll CU; Mao L; Starr HL; Alphs L
CNS Spectr; 2016 Dec; 21(6):466-477. PubMed ID: 27629292
[TBL] [Abstract][Full Text] [Related]
4. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
Rosa F; Schreiner A; Thomas P; Sherif T
Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
[TBL] [Abstract][Full Text] [Related]
5. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics.
Hargarter L; Cherubin P; Bergmans P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Schreiner A
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():1-7. PubMed ID: 25448776
[TBL] [Abstract][Full Text] [Related]
6. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
7. Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients.
Petrić D; Rački V; Gačo N; Kaštelan A; Graovac M
J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):197-204. PubMed ID: 30758986
[TBL] [Abstract][Full Text] [Related]
8. Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics.
Schreiner A; Bergmans P; Cherubin P; Keim S; Llorca PM; Cosar B; Petralia A; Corrivetti G; Hargarter L
J Psychopharmacol; 2015 Aug; 29(8):910-22. PubMed ID: 25999398
[TBL] [Abstract][Full Text] [Related]
9. Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.
Mathews M; Pei H; Savitz A; Nuamah I; Hough D; Alphs L; Gopal S
Clin Drug Investig; 2018 Aug; 38(8):695-702. PubMed ID: 29882073
[TBL] [Abstract][Full Text] [Related]
10. Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study.
Gattaz WF; Campos JA; Lacerda AL; Henna E; Ruschel SI; Bressan RA; de Oliveira IR; Rocha FL; Grabowski HM; Sacomani E; Louzã MR; Quevedo J; Elkis H; Zorzetto Filho D; Périco Cde A; Lawson FL; Appolinário JC
Curr Med Res Opin; 2014 Apr; 30(4):695-709. PubMed ID: 24289141
[TBL] [Abstract][Full Text] [Related]
11. A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents.
Schreiner A; Bergmans P; Cherubin P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Hargarter L
Clin Ther; 2014 Oct; 36(10):1372-88.e1. PubMed ID: 25444566
[TBL] [Abstract][Full Text] [Related]
12. Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia.
Hargarter L; Bergmans P; Cherubin P; Keim S; Conca A; Serrano-Blanco A; Bitter I; Bilanakis N; Schreiner A
Expert Opin Pharmacother; 2016 Jun; 17(8):1043-53. PubMed ID: 27042990
[TBL] [Abstract][Full Text] [Related]
13. Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics.
Kwon JS; Kim SN; Han J; Lee SI; Chang JS; Choi JS; Lee HJ; Cho SJ; Jun TY; Lee SH; Han C; Lee KU; Lee KK; Lee E
Int Clin Psychopharmacol; 2015 Nov; 30(6):320-8. PubMed ID: 26196188
[TBL] [Abstract][Full Text] [Related]
14. The effect of long-acting paliperidone palmitate once-monthly on negative and depressive symptoms in patients with schizophrenia switched from previous unsuccessful treatment with oral aripiprazole.
Schreiner A; Bergmans P; Cherubin P; Hargarter L
Ther Adv Psychopharmacol; 2017 Feb; 7(2):59-65. PubMed ID: 28255435
[TBL] [Abstract][Full Text] [Related]
15. Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment: Post hoc analysis of an open-label, prospective study.
Si TM; Cai SL; Zhuo JM; Zhang LL
Medicine (Baltimore); 2019 Jan; 98(3):e13688. PubMed ID: 30653088
[TBL] [Abstract][Full Text] [Related]
16. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
Joshi K; Pan X; Wang R; Yang E; Benson C
Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
[TBL] [Abstract][Full Text] [Related]
17. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
18. The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia.
El Khoury AC; Pilon D; Morrison L; Shak N; Vermette-Laforme M; Amos TB; Kim E; Lefebvre P
Curr Med Res Opin; 2019 Mar; 35(3):395-405. PubMed ID: 30526125
[TBL] [Abstract][Full Text] [Related]
19. Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR).
Schreiner A; Hargarter L; Hitschfield K; Lee JI; Lenskaya I; Sulaiman AH; Diels J;
Curr Med Res Opin; 2014 Jul; 30(7):1279-89. PubMed ID: 24597755
[TBL] [Abstract][Full Text] [Related]
20. Effects on Satisfaction and Service Engagement of Paliperidone Palmitate Compared with Oral Paliperidone in Patients with Schizophrenia: An Open Label Randomized Controlled Trial.
Bozzatello P; Bellino S; Mancini I; Sandei L; Zanalda E; Rocca P
Clin Drug Investig; 2019 Feb; 39(2):169-178. PubMed ID: 30523522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
